Good_老虎社区_美港股上老虎

Vinie Soh
2021-11-25

Good

Recently IPOd Biofrontera surges 146% following Roth buy initiation; sees 660% upside

Shares of Biofrontera (BFRI+147.1%) have skyrocketed today after Roth Capital initiated the stock wi

Recently IPOd Biofrontera surges 146% following Roth buy initiation; sees 660% upside

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":877093430,"tweetId":"877093430","gmtCreate":1637835980792,"gmtModify":1637835980792,"author":{"id":4099923234941180,"authorId":4099923234941180,"authorIdStr":"4099923234941180","name":"Vinie Soh","avatar":"https://static.tigerbbs.com/d3cec26f2c00c8fcedd689a7af49cda4","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":3,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Good</p></body></html>","htmlText":"<html><head></head><body><p>Good</p></body></html>","text":"Good","highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/877093430","repostId":1151788011,"repostType":4,"repost":{"id":"1151788011","pubTimestamp":1637829157,"share":"https://www.laohu8.com/m/news/1151788011?lang=&edition=full","pubTime":"2021-11-25 16:32","market":"us","language":"en","title":"Recently IPOd Biofrontera surges 146% following Roth buy initiation; sees 660% upside","url":"https://stock-news.laohu8.com/highlight/detail?id=1151788011","media":"seekingalpha","summary":"Shares of Biofrontera (BFRI+147.1%) have skyrocketed today after Roth Capital initiated the stock wi","content":"<p>Shares of Biofrontera (BFRI+147.1%) have skyrocketed today after Roth Capital initiated the stock with a buy rating and a $20 price target (~660% upside).</p>\n<p>Analyst Jonathan Aschoff says his rating and target is based on future revenue for&nbsp;Ameluz (aminolevulinic acid) and Xepi (ozenoxacin) cream for, respectively, actinic keratosis and impetigo.</p>\n<p>The company also markets BF-RhodoLed, and LED lamp emitting red light that is used in combination with Ameluz actinic keratosis.</p>\n<p>Biofrontera priced its October&nbsp;IPO at $5/share.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Recently IPOd Biofrontera surges 146% following Roth buy initiation; sees 660% upside</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRecently IPOd Biofrontera surges 146% following Roth buy initiation; sees 660% upside\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-25 16:32 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3774327-recently-ipod-biofrontera-surges-146-following-roth-buy-initiation-sees-660-upsoide><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Biofrontera (BFRI+147.1%) have skyrocketed today after Roth Capital initiated the stock with a buy rating and a $20 price target (~660% upside).\nAnalyst Jonathan Aschoff says his rating and ...</p>\n\n<a href=\"https://seekingalpha.com/news/3774327-recently-ipod-biofrontera-surges-146-following-roth-buy-initiation-sees-660-upsoide\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BFRI":"Biofrontera Inc"},"source_url":"https://seekingalpha.com/news/3774327-recently-ipod-biofrontera-surges-146-following-roth-buy-initiation-sees-660-upsoide","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1151788011","content_text":"Shares of Biofrontera (BFRI+147.1%) have skyrocketed today after Roth Capital initiated the stock with a buy rating and a $20 price target (~660% upside).\nAnalyst Jonathan Aschoff says his rating and target is based on future revenue for Ameluz (aminolevulinic acid) and Xepi (ozenoxacin) cream for, respectively, actinic keratosis and impetigo.\nThe company also markets BF-RhodoLed, and LED lamp emitting red light that is used in combination with Ameluz actinic keratosis.\nBiofrontera priced its October IPO at $5/share.","news_type":1},"isVote":1,"tweetType":1,"viewCount":536,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}